Alma Technologies Launches Scalable Encoder and Decoder Semiconductor IP for VESA DSC 1.2b Visually Lossless Compression
30.3.2022 15:01:00 EEST | Business Wire | Press release
IP Highlights:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220330005026/en/
Extending Alma Technologies UHT™ Image & Video Compression product line, the new UHT-DSC-E and UHT-DSC-D IP cores provide ultra-low latency visually lossless compression across display interfaces and devices. (Graphic: Business Wire)
- Fully compliant with VESA DSC 1.2b and backwards compatible with DSC 1.1
- Ultra-low latency visually lossless image compression for all types of content
- Scalable architecture supporting up to 10K @120Hz with native pixel coding and up to 16 bits per color for high color depth and HDR content
- Compatible with major transport standards including MIPI DSI, VESA DisplayPort 1.4 and HDMI 2.1
Alma Technologies S.A. today announced its new UHT-DSC-E and UHT-DSC-D DSC 1.2b encoder and decoder IP cores that enable the transport of high-definition content with up to 10K resolution, 120Hz refresh rate, high dynamic range and high color depth through existing interfaces, such as VESA DisplayPort, MIPI DSI and HDMI 2.1.
Extending Alma Technologies UHTTM Image and Video Compression family of JPEG, JPEG 2000 and H.264 IP, these ultra-high throughput and scalable performance semiconductor IP implementations of the DSC 1.2b standard provide a fully accelerated, standalone and robust compression solution in a single IP instance, saving on ASIC or FPGA silicon area and power. The cores do not need an external memory device for their implementation and lower power consumption for longer battery life is further enabled by the reduced video interface data rates and video buffer sizes.
The new Alma Technologies encoder and decoder IP cores for DSC 1.2b are very easy-to-use and integrate in a system. They are self-contained, CPU-less, complete H/W implementations and are available either in RTL source code, or as pre-synthesized Netlists for all major FPGA vendor devices.
Contact us online at www.alma-technologies.com/contact, or call us at +30-210-603-9850 to learn more.
About Alma Technologies
Alma Technologies is a semiconductor IP provider, designing high-quality FPGA and ASIC IP cores since 2001. Its products stand out for their engineering, being complete, easy-to-use and reliable IP solutions. World-class technical support and a long track record of proven designs by more than 250 licensees in over 20 countries provide Alma Technologies customers with excellent service and great value.
UHT is a trademark of Alma Technologies.
All other trademarks and trade names are the property of their respective owners.
###
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005026/en/
Contact information
Vassilis Spiliotopoulos
media@alma-technologies.com
+30-210-603-9850 ext.107
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
Zayed Sustainability Prize Closes 2027 Submissions with Strong Global Participation13.7.2026 12:48:00 EEST | Press release
The Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, has officially closed submissions for its 2027 awards cycle, receiving an unprecedented 10,233 entries from 177 countries across its six categories of Health, Food, Energy, Water, Climate Action and Global High Schools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713519403/en/ Zayed Sustainability Prize Closes 2027 Submissions with Strong Global Participation (Photo: AETOSWire) Now in its 18th year, the Prize continues to attract a diverse and growing pool of small and medium-sized enterprises, nonprofit organisations and high schools developing solutions that improve lives, particularly in vulnerable and underserved communities. This year’s submissions point to a growing emphasis on resilience, adaptability and systems-level impact. Across regions, applicants are addressing complex global challenges through practi
Ant Group Open-Sources SingGuard-NSFA to Establish New Security Paradigms for Autonomous AI Agents13.7.2026 12:01:00 EEST | Press release
Ant Group’s AI Security Lab today announced the open-source release of SingGuard-NSFA, a specialized security guardrail framework designed specifically for autonomous AI agents. The framework secures agentic AI systems against operational threats like prompt injection, addressing critical vulnerabilities as AI transitions from passive content generation to active, autonomous execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712722454/en/ As AI agents rapidly move from research labs to business scenarios, the security landscape has fundamentally shifted. The explosive global adoption of open-source agent frameworks like OpenClaw, celebrated for their "one-click deployment" and "full-stack autonomy", has simultaneously exposed significant operational risks, including permission escalation and prompt injection. Industry frameworks, including the OWASP (Open Web Application Security Project) Top 10 for Agentic Applica
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 11:00:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Gi
Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 11:00:00 EEST | Press release
Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasing demand for AI, but for managed services, which acts as a cost-savings lever to help fund AI ambitions and continued digital
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom